• UCB SA highlighted new research in generalized myasthenia gravis that evaluates “minimal symptom expression” as a patient-centered treatment outcome.
• Findings are being presented this week at the AANEM annual meeting and the MGFA Scientific Session.
• The work focuses on how often patients can reach a state with minimal day-to-day symptom impact.
• It uses a patient-reported daily-living questionnaire rather than clinician-led assessments alone.
• UCB framed the research as supporting a shift in treatment goals toward outcomes that better reflect real-world functioning and quality of life.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. UCB SA published the original content used to generate this news brief on September 28, 2026, and is solely responsible for the information contained therein.